Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition requiring individualized treatment based largely on the patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. It is traditionally treated with established drugs such as rizatriptan, diclofenac, flunarizine, lomerizine, and topiramate but these treatments have limited efficacy and undesirable side effects. Thus, there is significant unmet need for more-efficacious migraine-specific prophylactic therapies. Several acute and preventive therapies for migraine are expected to launch during the 2022-2032 period. In this report, we explore how unmet need, pricing, coverage, and regulatory reforms in the access and reimbursement landscape of China will likely impact the success of current and future players in this highly lucrative market.
1. How large is China’s drug-treatable migraine population, and how will drug-treatment rates change during the forecast period?
2. What events will shape the acute / preventive and episodic / chronic market segments?
3. What are interviewed experts’ insights into current treatment options?
4. What are the key unmet needs in the management of migraine in China?
5. What are the key market access considerations, and how will they impact the uptake of emerging therapies for migraine in China?
6. What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, includingworld-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 52 surveys with neurologists and PCPs. Supported by survey data collected for this and other Clarivate research
Diagnosed prevalence of migraine in urban versus rural China; clinically relevant and market-relevant, drug-treatable populations
10-year, annualized, drug-level sales and patient shares of key migraine agents through 2032, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 8 drugs; Phase I: 1 drug